Meridian Wealth Management LLC Increases Holdings in Merck & Co., Inc. $MRK

Meridian Wealth Management LLC increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 11.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,604 shares of the company’s stock after purchasing an additional 7,950 shares during the quarter. Meridian Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $10,229,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. D.A. Davidson & CO. lifted its position in Merck & Co., Inc. by 4.4% during the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares during the period. Pinnbrook Capital Management LP grew its stake in shares of Merck & Co., Inc. by 95.2% in the 4th quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock valued at $2,450,000 after purchasing an additional 11,355 shares during the last quarter. Cibc World Market Inc. increased its holdings in shares of Merck & Co., Inc. by 32.6% in the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock valued at $137,022,000 after purchasing an additional 320,143 shares during the period. Handelsbanken Fonder AB increased its holdings in shares of Merck & Co., Inc. by 13.9% in the fourth quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock valued at $193,999,000 after purchasing an additional 224,752 shares during the period. Finally, Panagora Asset Management Inc. raised its stake in shares of Merck & Co., Inc. by 410.5% during the fourth quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock worth $74,255,000 after purchasing an additional 567,249 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $152.43 on Monday. The business has a 50 day moving average price of $128.09 and a 200 day moving average price of $121.29. The company has a market capitalization of $376.07 billion, a P/E ratio of 121.94, a PEG ratio of 6.40 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $154.49. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts expect that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Insiders Place Their Bets

In related news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the sale, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by company insiders.

Analysts Set New Price Targets

MRK has been the subject of several recent research reports. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday. BMO Capital Markets boosted their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday. Royal Bank Of Canada downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and upped their price objective for the stock from $142.00 to $150.00 in a research report on Thursday. JPMorgan Chase & Co. raised their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Guggenheim lifted their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.10.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.